Cerenkov luminescence imaging of medical isotopes Journal Article


Authors: Ruggiero, A.; Holland, J. P.; Lewis, J. S.; Grimm, J.
Article Title: Cerenkov luminescence imaging of medical isotopes
Abstract: The development of novel multimodality imaging agents and techniques represents the current frontier of research in the field of medical imaging science. However, the combination of nuclear tomography with optical techniques has yet to be established. Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies. Methods: In vitro phantom studies were used to validate the visible light emission observed from a range of radionuclides including the positron emitters18F,64Cu,89Zr, and124I; b-emitter131I; and α-particle emitter 225Ac for potential use in CLI. The novel radiolabeled monoclonal antibody89Zr-desferrioxamine B [DFO]-J591 for immuno-PET of prostate-specific membrane antigen (PSMA) expression was used to coregister and correlate the CLI signal observed with the immuno-PET images and biodistribution studies. Results: Phantom studies confirmed that Cerenkov radiation can be observed from a range of positron-, β-, and α-emitting radionuclides using standard optical imaging devices. The change in light emission intensity versus time was concordant with radionuclide decay and was also found to correlate linearly with both the activity concentration and the measured PET signal (percentage injected dose per gram). In vivo studies conducted in male severe combined immune deficient mice bearing PSMA-positive, subcutaneous LNCaP tumors demonstrated that tumor-specific uptake of89Zr-DFO-J591 could be visualized by both immuno-PET and CLI. Optical and immuno-PET signal intensities were found to increase over time from 24 to 96 h, and biodistribution studies were found to correlate well with both imaging modalities. Conclusion: These studies represent the first, to our knowledge, quantitative assessment of CLI for measuring radiotracer uptake in vivo. Many radionuclides common to both nuclear tomographic imaging and radiotherapy have the potential to be used in CLI. The value of CLI lies in its ability to image radionuclides that do not emit either positrons or γ-rays and are, thus, unsuitable for use with current nuclear imaging modalities. Optical imaging of Cerenkov radiation emission shows excellent promise as a potential new imaging modality for the rapid, high-throughput screening of radiopharmaceuticals. COPYRIGHT © 2010 by the Society of Nuclear Medicine, Inc.
Keywords: controlled study; unclassified drug; nonhuman; outcome assessment; positron emission tomography; radiopharmaceuticals; neoplasm; neoplasms; prostate specific antigen; animal cell; mouse; animal; metabolism; animals; mice; animal tissue; image analysis; animal experiment; animal model; in vivo study; drug screening; validation study; drug evaluation, preclinical; diagnostic imaging; monoclonal antibodies; monoclonal antibody; prostate-specific antigen; prostatic neoplasms; immunology; monoclonal antibody j591; prostate specific membrane antigen; antibodies, monoclonal; diagnostic agent; drug distribution; isotope labeling; tissue distribution; luminescence; image quality; prostate tumor; positron-emission tomography; radiopharmaceutical agent; scintiscanning; iodine 124; radioisotope; neoplasm transplantation; phantom; phantoms, imaging; tumor; immune deficiency; fluorine 18; pet; radioisotopes; drug tumor level; electrons; isotope; zirconium; deferoxamine; cell strain lncap; electron; cancer transplantation; j591; alpha radiation; infrared radiation; 131i; 89zr; prostate-specific membrane antigen (psma); alpha particles; 124i; 18f; 225ac; 64cu; cerenkov; imaging technology; optical imaging; radioimmunoconjugate; desferrioxamine b monoclonal antibody j591 zr 89; cerenkov luminescence imaging; light intensity; beta particles
Journal Title: Journal of Nuclear Medicine
Volume: 51
Issue: 7
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2010-07-01
Start Page: 1123
End Page: 1130
Language: English
DOI: 10.2967/jnumed.110.076521
PUBMED: 20554722
PROVIDER: scopus
PMCID: PMC3068779
DOI/URL:
Notes: --- - "Cited By (since 1996): 4" - "Export Date: 20 April 2011" - "CODEN: JNMEA" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Jason Philip Holland
    30 Holland
  2. Jan Grimm
    55 Grimm
  3. Jason S Lewis
    248 Lewis